http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Bioventus Reports First Quarter Financial Results
-
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
-
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
-
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
-
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
-
Bioventus Reports Third Quarter Financial Results
-
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
-
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
-
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
-
Bioventus Reports Second Quarter Financial Results
-
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
-
Bioventus Reports First Quarter Financial Results
-
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
-
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
-
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
-
Bioventus (BVS) Enters into an Amendment to Enhance Financial and Operational Flexibility
-
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
-
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
-
Bioventus (BVS) Appoints Robert Claypoole as CEO and President
-
Bioventus Names Robert Claypoole as President and Chief Executive Officer
-
Bioventus (BVS) Agrees to Nationwide Contract with Aetna Medicare Advantage Plans for DUROLANE for Knee Osteoarthritis
-
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
-
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
-
Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023
-
Bioventus to Present at the Cantor Global Healthcare Conference
-
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
-
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
-
Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
-
Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
-
Bioventus Completes Divestiture of its Wound Business
-
Bioventus Reports First Quarter Financial Results
-
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
-
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
-
Bioventus Announces Divestiture of its Wound Business
-
Bioventus (BVS) Announces CEO Leadership Change
-
Bioventus Announces CEO Leadership Change
-
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
-
Bioventus (BVS) Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
-
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
-
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
-
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
-
Bioventus (BVS) Enters Settlement Agreement
-
Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition
-
Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
-
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022
-
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance
-
Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022
-
Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago

